Skip to content

Orthofix Medical Inc. OFIX Debt Issuance Costs

Debt Issuance Costs at other companies

Bioventus logo
BioventusBVS
$174.25K-40.9%
Carlsmed, Inc. Common Stock logo
Carlsmed, Inc. Common StockCARL
$0-100%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$0-100%

Other financials

Income statement

See full
Revenue$196.7M+1.6%
Gross profit$139.5M+14.7%
Operating income-$14.4M+70.5%
Net income-$20.9M+60.6%
EPS (diluted)-$0.52+61.5%

Balance sheet

See full
Cash & equivalents$120.3M+108%
Total debt$237.5M+32.3%
Total equity$435.2M-5.0%
Total assets$886.6M+7.7%

Cash flow

See full
Operating cash flow-$17.6M+4.2%
CapEx$10.7M+58.3%
Free cash flow-$28.3M-12.5%

Valuation

See full
Market cap$376.33M-7.1%
Enterprise value$493.54M-6.3%
P/S0.5×0.0×

Profitability

See full
Gross margin70.7%+3.6pp
Operating margin-5.8%-2.1pp
Net margin-7.3%-2.7pp
FCF margin-9.3%-1.7pp

Returns & leverage

See full
Return on equity-13.4%-4.6pp
Debt / equity0.5×+0.2×
Current ratio2.9×+0.2×

Where this comes from

Reported directly by Orthofix Medical Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Orthofix Medical Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Orthofix Medical Inc.'s debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Orthofix Medical Inc.'s debt issuance costs?
Orthofix Medical Inc. (OFIX) reported debt issuance costs of $24K in Q1 2026.
How has Orthofix Medical Inc.'s debt issuance costs changed year-over-year?
Orthofix Medical Inc.'s debt issuance costs decreased by 95.3% year-over-year, from $512K to $24K.
What is the long-term trend for Orthofix Medical Inc.'s debt issuance costs?
Over 2 years (2021 to 2024), Orthofix Medical Inc.'s debt issuance costs has grown at a 95.7% compound annual growth rate (CAGR), from $948K to $3.63M.
What does debt issuance costs mean?
Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.